TZ-2 — Dual Incretin Receptor Agonist Peptide
TZ-2 is a high-purity research peptide that functions as a dual incretin receptor agonist, simultaneously engaging both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism targets two key metabolic signaling pathways involved in glucose homeostasis and energy regulation.
Mechanism of Action
TZ-2 activates GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon release, while simultaneously stimulating GIP receptors to amplify incretin signaling and improve beta-cell responsiveness. The dual agonism produces complementary metabolic effects: GLP-1 receptor activation slows gastric emptying and modulates appetite signaling, while GIP receptor engagement enhances the insulinotropic response and may influence lipid metabolism in adipose tissue.
Research Applications
- Dual incretin pathway modulation studies
- Glucose homeostasis and insulin secretion research
- GLP-1 and GIP receptor co-activation mechanisms
- Appetite regulation and energy balance investigations
- Comparative studies with single-receptor agonists
- Beta-cell function and pancreatic islet research
Product Specifications
- Quantity: 10mg per vial
- Purity: ≥99% (HPLC verified)
- Form: Lyophilized powder
- Storage: Refrigerate after reconstitution
- Testing: USA lab tested, COA available
For research purposes only. Not for human use or consumption.
26 reviews for TZ-2 (Tirz)